HK Stock Market Move | ANTENGENE-B(06996) rises by over 14% again, with a cumulative increase of 1.7 times in the month. The company plans to increase investment in AI drug research and development.

ANTENGENE-B (06996) has risen by over 14%, with a cumulative increase of over 170% within the month. As of the publication, it has risen by 14.36% to 2.15 HKD, with a turnover of 13.5983 million HKD. On the news front, Deqi Pharmaceuticals announced plans to increase investment and establish a dedicated AI department to integrate resources. This initiative includes the local deployment of DeepSeek to accelerate the development of the T Cell Engaging (TCE) platform with spatial bit occlusion effect. It is reported that the company had already invested as an angel investor in the Hangzhou Deruizhi Medicine AI drug discovery platform in 2021, strategically entering the field of AI drug discovery. The company has also successfully discovered a new liver cancer-related antigen (TAA) through AI data modeling combined with multi-omics analysis, and has developed it into a TCE candidate drug entering the preclinical validation stage.